Key facts
- Qiagen is reportedly attracting early takeover interest from private equity firms EQT AB, Advent, and KKR.
- The company is exploring strategic options, including a potential sale.
- Qiagen's supervisory board is evaluating preliminary interest from potential buyers.
- UBS maintained a Neutral rating and $50.00 price target on Qiagen.
Qiagen is reportedly attracting early takeover interest from private equity firms, including EQT AB, Advent International, and KKR & Co., according to Bloomberg News. The company is exploring strategic options, which may include a sale, and has been working with advisers to evaluate preliminary interest from potential buyers.
Qiagen's stock saw a significant jump of 18.2% over the past week, trading at $54.61, just below its 52-week high of $58.63. Despite this movement, UBS maintained its Neutral rating and $50.00 price target, noting the difficulty in assessing the likelihood of a deal materializing. UBS identified potential obstacles in deal negotiations, including a gap between Qiagen's projected 7% organic sales growth and UBS's more conservative 4-5% estimate. Valuation disparities among industry peers were also highlighted, with European competitors trading at approximately 11 times 2026 EBITDA, while U.S. peers command multiples exceeding 20 times. Revvity, a comparable company, trades at 17 times 2026 EBITDA.
Furthermore, UBS pointed out that Qiagen's recent growth has partly depended on latent TB testing, a market Roche plans to enter soon, which could complicate Qiagen's future growth outlook. The discussions with potential buyers, including some U.S.-based strategic companies, follow recent talks and come as Qiagen continues to assess its future direction and opportunities.